Clinical trials
Early Stage Breast Carcinoma clinical trials
Below are recruiting early stage breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 147 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06627712RecruitingPhase 3
SBRT with immunotherapy and chemo for early-stage triple-negative breast cancer
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
Sichuan, ChengduAges 18–65 - NCT07459673RecruitingPhase 2
HER2-positive breast cancer trial using ctDNA to guide treatment
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
Basking Ridge, New JerseyAges 18 years+ - NCT07616453RecruitingPhase 2
New Drug Plus Hormone Therapy for Hormone-Responsive Breast Cancer
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT07151911Recruiting
Study of drugs for high-risk early breast cancer
This study looks at the effectiveness of the drugs abemaciclib and olaparib plus hormone therapy for people with high-risk, hormone receptor-positive, HER2-negative early breast cancer. It aims to understand how well these treatments work in real-world settings.
Modena, ModenaAges 18 years+ - NCT06236269RecruitingPhase 2
Sacituzumab Govitecan for HR+/HER2- advanced breast cancer
This trial tests a drug called Sacituzumab Govitecan for people with HR+/HER2- advanced or metastatic breast cancer that has stopped responding to a CDK4/6 inhibitor. It looks at whether the drug can slow down the cancer and requires you to have a tumor biopsy.
Badalona, BarcelonaAges 18 years+ - NCT05570825RecruitingPhase 2
Study drug SX-682 with pembrolizumab for advanced lung cancer
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
Seattle, WashingtonAges 18 years+ - NCT07017829RecruitingPhase 2
GT103 plus pembrolizumab for STK11 mutant lung cancer
This trial tests a new drug called GT103 combined with the immunotherapy pembrolizumab (Keytruda) for people with advanced lung cancer that has a specific genetic change (STK11 mutation) and has continued to grow despite prior pembrolizumab treatment. The goal is to see if adding GT103 can help shrink tumors or slow the cancer's growth.
Buffalo, New YorkAges 18 years+ - NCT05861271RecruitingPhase 2
Adjuvant pyrotinib plus capecitabine for tiny HER2 breast cancer
This trial studies whether adding pyrotinib and capecitabine after surgery can lower the risk of cancer coming back in people with very small, lymph-node–negative, HER2-positive breast cancer. It’s for patients who fit specific tumor size and HER2 test results and who can safely take chemotherapy-like medicines and stay on contraception during treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04543799Recruiting
Sleep quality study in prostate and early breast cancer patients
This trial studies how sleep quality changes while people with prostate cancer or early breast cancer receive standard treatments. It may help doctors understand which treatment factors affect sleep and identify who might benefit from support for sleep problems.
BellinzonaAges 18 years+ - NCT07019363RecruitingPhase 3
CDK4/6 inhibitor plus hormone therapy for high-risk breast cancer
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
ShanghaiAges 18–70 - NCT07135661Recruiting
Comparing two proton radiation schedules for early breast cancer after lumpectomy
This study compares two types of proton radiation after lumpectomy for early breast cancer. It tests whether a shorter, stronger course (ultra-hypofractionated) works as well as a slightly longer moderate course.
ShanghaiAges 40 years+ - NCT06606730RecruitingPhase 3
Personalized pembrolizumab after strong chemo response for early triple-negative breast cancer
This trial is for people with early triple-negative breast cancer who had a strong response to chemotherapy combined with pembrolizumab before surgery. It aims to find the best way to continue using pembrolizumab after surgery to reduce the risk of cancer coming back.
BrusselsAges 18 years+ - NCT05306041RecruitingPhase 2
Pre-surgery hormone therapy with or without PI3K inhibitor
This trial tests whether giving hormone-blocking treatment before surgery works better when combined with an added targeted drug for certain breast cancers. It may help shrink the tumor and improve outcomes for people whose tumors have specific hormone and genetic features.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT07635342RecruitingPhase 2
Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
Shijiazhuang, HebeiAges 18–65 - NCT07647263RecruitingPhase 2
New Drug Treatment Before Surgery for HER2-Positive Breast Cancer
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
Suzhou, JiangsuAges 18 years+ - NCT05502523Recruiting
Blood test DNA levels after lung surgery
This study looks at how different lung surgical techniques affect levels of tumor DNA in the blood before and after surgery for early-stage lung cancer. It may help doctors choose surgical approaches and use a blood test to monitor cancer after surgery.
Abington, PennsylvaniaAges 18 years+ - NCT06470347RecruitingPhase 1/Phase 2
Testing Pyrrolitinib After Trastuzumab for HER2+ Breast Cancer
This study tests if taking pyrrolitinib (a targeted medicine) can further reduce the risk of breast cancer returning in patients with HER2-positive early breast cancer who have already received trastuzumab after surgery.
Zunyi, GuizhouAges 18–75 - NCT04469296Recruiting
Diet changes before surgery for hormone-receptor breast cancer
This trial tests whether changing your diet before your breast surgery can help people with early, hormone-receptor (ER/PR+) breast cancer. It focuses on patients who have not started treatment yet and want to keep surgery as the main treatment.
Montpellier, HeraultAges 18–80 - NCT05891093RecruitingPhase 3
Fluzoparib plus hormone therapy after surgery for breast cancer
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
Beijing, Beijing MunicipalityAges 18–70 - NCT07237256RecruitingPhase 3
Testing less chemo for HR+ HER2- breast cancer with ribociclib
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
AmiensAges 18 years+ - NCT04151940Recruiting
PET/CT scan changes during chemo with immune therapy
This study looks at how PET/CT scan results change while you receive chemo plus an immune therapy (a PD-1/PD-L1 medicine) for stage IV lung cancer. The goal is to better understand what the scans mean during treatment, which may help guide care in the future.
Seattle, WashingtonAges 18 years+ - NCT06492616RecruitingPhase 3
Elacestrant vs standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
Daphne, AlabamaAges 18 years+ - NCT03408353Recruiting
MERIT study uses mammogram and blood tests to assess breast cancer risk
This study looks for signs in blood samples and imaging that may help estimate breast cancer risk earlier. You would do a mammogram and give blood at the start and then again at yearly follow-up visits.
Houston, TexasAges 25–80 - NCT06328465Recruiting
MRI for early detection of breast cancer spread
This trial is testing a new way to use MRI scans to find breast cancer that has spread to other parts of the body early. It is for people who have had aggressive breast cancer (HER2 positive or triple negative) and finished treatment with surgery, but still have a higher risk of the cancer coming back.
MilanAges 18–75
Hear when a new Early Stage Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for early stage breast carcinoma?
- Yes. Clin2 currently lists 147 recruiting early stage breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a early stage breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a early stage breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.